American Thoracic Society - Sanofi Investor Call
Itepekimab: Positive Aerify interim analysis
AERIFY-1
Itepekimab Q2W SC
Population
40-85 yrs
Mod-to-severe COPD
w/smoking history of
>10 pack-years
N=930
Population
40-85 yrs
Mod-to-severe COPD
w/smoking history of
≥10 pack-years
N=1,170
Randomization
Itepekimab Q4W SC
Placebo SC
Follow-up
Former
Smokers
PBO + MFNS
3-5-Week
Week 0
Screening Period
Week 52
Primary Endpoint
Week 72
End of Follow-up
Randomization
3-5-Week
Screening Period
Itepekimab is under investigation and not yet approved by any regulatory agency.
38 ATS Investor Call
AERIFY-2
Itepekimab Q2W SC
Itepekimab Q4W SC
Placebo SC
Itepekimab Q2W SC
Follow-up
Former
Smokers
Current
Smokers
Placebo SC
PBO MFNS
Week 0
Week 52
Primary Endpoint
Week 72
End of Follow-up
sanofi
FDA Fast Track
Designation for COPD in
former smokers in
January 2023
Phase 3 data from
AERIFY 1 & AERIFY 2
expected in 2025View entire presentation